Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
2.660
+0.160 (6.40%)
At close: Nov 7, 2025, 4:00 PM EST
2.670
+0.010 (0.38%)
After-hours: Nov 7, 2025, 7:54 PM EST
Esperion Therapeutics Revenue
Esperion Therapeutics had revenue of $87.31M in the quarter ending September 30, 2025, with 69.10% growth. This brings the company's revenue in the last twelve months to $303.80M, up 2.83% year-over-year. In the year 2024, Esperion Therapeutics had annual revenue of $332.31M with 185.66% growth.
Revenue (ttm)
$303.80M
Revenue Growth
+2.83%
P/S Ratio
1.73
Revenue / Employee
$999,349
Employees
304
Market Cap
635.91M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 332.31M | 215.98M | 185.66% |
| Dec 31, 2023 | 116.33M | 40.86M | 54.14% |
| Dec 31, 2022 | 75.48M | -2.97M | -3.79% |
| Dec 31, 2021 | 78.45M | -149.10M | -65.52% |
| Dec 31, 2020 | 227.55M | 79.18M | 53.37% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ESPR News
- 1 day ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 1 day ago - Esperion Therapeutics, Inc. (ESPR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer - GlobeNewsWire
- 12 days ago - Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025 - GlobeNewsWire
- 4 weeks ago - Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
- 4 weeks ago - Esperion Announces Pricing of Public Offering of Common Stock - GlobeNewsWire
- 4 weeks ago - Esperion Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 5 weeks ago - Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040 - GlobeNewsWire